NEW YORK (360Dx) – The Federal Trade Commission said today that Becton Dickinson and CR Bard have agreed to divest two medical device product lines to settle its complaint that the proposed $24-billion acquisition would negatively impact competition.

Under the settlement, BD will divest its soft tissue core-needle biopsy product line and CR Bard will divest its Aspira product line of tunneled home drainage catheters and accessories.